Search
Ruijian Pharmaceuticals' newly established Chengdu headquarters has officially commenced operations within Tianfu International Biocity, solidifying its position as a hub for cell therapy drug research, development, and production. In a strategic partnership with Danaher, the company has launched an innovation center dedicated to AI-powered cell therapy R&D. NouvNeu001, their flagship product aimed at treating Parkinson's disease, has secured clinical approval in both China and the United States and has advanced to Phase II trials, showcasing impressive safety and efficacy profiles. Leveraging its AI+chemical induction platform, Ruijian Pharmaceuticals is not only accelerating technological advancements but also bolstering its industrialization capabilities, while fostering deeper ties with the Chengdu biopharmaceutical industry.
-
C114 Communication Network -
Communication Home
